SCHEMBL22228753

SCHEMBL22228753

Cc1cnc(NC2CCC(C(=O)O)CC2)nc1-c1cnc2ccc(Br)cn12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 3/20 0.60
▸ CCNT1 O60563 1/20 0.60
▸ CDK9 P50750 1/20 0.60
▸ EIF2AK4 Q9P2K8 2/20 0.42
▸ MAPK8 P45983 4/20 0.41
▸ MAPK9 P45984 4/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ JUN P05412 2/20 0.41
▸ TRIM24 O15164 2/20 0.40
▸ TRIM33 Q9UPN9 2/20 0.40
▸ IGF1R P08069 3/20 0.39
▸ MAPK10 P53779 1/20 0.38
▸ ADRA2A P08913 2/20 0.36
▸ HRH1 P35367 2/20 0.36
▸ HTR2B P41595 2/20 0.36
▸ MCHR1 Q99705 2/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ MAP3K14 Q99558 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22228756 1.00 FLT3 (0.60) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL31500973 0.91 FLT3 (0.56) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL22228887 0.88 FLT3 (0.61) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL22228886 0.88 FLT3 (0.61) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL20455537 0.87 FLT3 (0.62) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL31501012 0.87 FLT3 (0.62) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL20455536 0.87 FLT3 (0.62) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL20455543 0.86 CDK9 (0.75) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL20455544 0.86 CDK9 (0.75) FLT3CCNT1CDK9EIF2AK4MAPK8
SCHEMBL20455831 0.86 FLT3 (0.61) FLT3CCNT1CDK9EIF2AK4MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-09-07 — — US disclosed
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS CDK2, CDKL1, CDKL2 FLT3 282/4885CCNT1 52/4885CDK9 7/4885
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents CDK2, CDKL1, CDKL2 FLT3 282/4885CCNT1 52/4885CDK9 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback